146 related articles for article (PubMed ID: 33370020)
1. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
Kessel E; Naparst M; Alpert N; Diaz K; Ahn E; Wolin E; Taioli E; Kim MK
Pancreas; 2021 Jan; 50(1):29-36. PubMed ID: 33370020
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
[TBL] [Abstract][Full Text] [Related]
3. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
4. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
5. Current Concepts in the Management of GEP-NETs: Introduction.
Iyer R
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):3-4. PubMed ID: 27167990
[No Abstract] [Full Text] [Related]
6. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
7. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
8. Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study.
Abdel-Rahman O; Fazio N
Pancreas; 2021 May-Jun 01; 50(5):727-731. PubMed ID: 34016894
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
10. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis.
Chan DT; Luk AO; So WY; Kong AP; Chow FC; Ma RC; Lo AW
BMC Endocr Disord; 2016 Feb; 16():12. PubMed ID: 26911576
[TBL] [Abstract][Full Text] [Related]
11. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis.
Singal V; Singal AK; Kuo YF
J Cancer Res Clin Oncol; 2012 Apr; 138(4):715-22. PubMed ID: 22246279
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.
Murphy MM; Simons JP; Ng SC; McDade TP; Smith JK; Shah SA; Zhou Z; Earle CC; Tseng JF
Ann Surg Oncol; 2009 Nov; 16(11):2968-77. PubMed ID: 19669839
[TBL] [Abstract][Full Text] [Related]
13. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.
Lai Y; Wang C; Civan JM; Palazzo JP; Ye Z; Hyslop T; Lin J; Myers RE; Li B; Jiang B; Sama A; Xing J; Yang H
Gastroenterology; 2016 May; 150(5):1135-1146. PubMed ID: 26836586
[TBL] [Abstract][Full Text] [Related]
14. Racial and Socioeconomic Disparities in the Treatments and Outcomes of Pancreatic Cancer Among Different Treatment Facility Types.
Zhu F; Wang H; Ashamalla H
Pancreas; 2020; 49(10):1355-1363. PubMed ID: 33122525
[TBL] [Abstract][Full Text] [Related]
15. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
[TBL] [Abstract][Full Text] [Related]
16. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.
Zeng C; Wen W; Morgans AK; Pao W; Shu XO; Zheng W
JAMA Oncol; 2015 Apr; 1(1):88-96. PubMed ID: 26182310
[TBL] [Abstract][Full Text] [Related]
17. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
18. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
Thapi S; Baeg K; Kim MK; Gallagher EJ
Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
[TBL] [Abstract][Full Text] [Related]
19. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
20. Cases in the Management of GEP-NETs: The Use of Surgery, an Underutilized Option in the Management of Advanced-Stage NETs.
Boudreaux JP
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):7-11. PubMed ID: 27167992
[No Abstract] [Full Text] [Related]
[Next] [New Search]